Minerva Neurosciences, Inc. Fair Value Adjustment of Warrants
Minerva Neurosciences, Inc. (NERV) reported Fair Value Adjustment of Warrants of -$27.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-07
- Minerva Neurosciences, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$27.55M.
- Minerva Neurosciences, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $109.36M.
- Minerva Neurosciences, Inc. fair value adjustment of warrants for fiscal 2025 was -$45.39M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|
| 2026-06-30 | -$27.55M 10-Q · filed 2026-08-07 | $81.81M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $109.36M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | -$45.39M 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |